Literature DB >> 2830582

Role of c-myc in the transformation of REF52 cells by viral and cellular oncogenes.

N E Kohl1, H E Ruley.   

Abstract

Cells of the established REF52 line completely resist stable transformation by activated ras oncogenes, apparently because expression of ras p21 above a low threshold level inhibits cell proliferation. Adenovirus E1A and simian virus 40 (SV40) large T antigen enable ras oncogenes to transform REF52 cells and therefore protect REF52 cells from ras-induced growth arrest. The present study investigated the role of c-myc in regulating the responses of REF52 cells to ras oncogenes. We report that transcriptionally activated c-myc oncogenes enabled ras to transform REF52 cells but the efficiency of transformation was 20- to 30-fold lower than with E1A. In contrast, myc and E1A were similarly active as ras collaborators when assayed on primary baby rat kidney (BRK) cells. Relative difficulties transforming REF52 celis by myc and ras did not result from a requirement to express either gene at higher levels in REF52 as compared with BRK transformants. Steady state levels of endogenous c-myc RNA were unaltered in REF52 cells transformed by ras together with c-myc, E1A or SV40 large T antigen. Furthermore, ras-induced growth arrest was not accompanied by a decline in c-myc RNA levels. These results suggest that transcriptional control of c-myc is not affected either by the anti-proliferative effects of ras or by the collaborating activities of E1A and SV40 large T antigen.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2830582

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  19 in total

1.  Phosphatidylinositol 3-kinase, Cdc42, and Rac1 act downstream of Ras in integrin-dependent neurite outgrowth in N1E-115 neuroblastoma cells.

Authors:  S Sarner; R Kozma; S Ahmed; L Lim
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

Review 2.  Balance of Yin and Yang: ubiquitylation-mediated regulation of p53 and c-Myc.

Authors:  Mu-Shui Dai; Yetao Jin; Jayme R Gallegos; Hua Lu
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

Review 3.  The viral etiology of AIDS-associated malignancies.

Authors:  Peter C Angeletti; Luwen Zhang; Charles Wood
Journal:  Adv Pharmacol       Date:  2008

4.  Mutant p53 tumor suppressor alleles release ras-induced cell cycle growth arrest.

Authors:  G G Hicks; S E Egan; A H Greenberg; M Mowat
Journal:  Mol Cell Biol       Date:  1991-03       Impact factor: 4.272

5.  Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway.

Authors:  K M Pumiglia; S J Decker
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

6.  Cell lines established by a temperature-sensitive simian virus 40 large-T-antigen gene are growth restricted at the nonpermissive temperature.

Authors:  P S Jat; P A Sharp
Journal:  Mol Cell Biol       Date:  1989-04       Impact factor: 4.272

Review 7.  The HL60 cell line: a model system for studying human myeloid cell differentiation.

Authors:  G D Birnie
Journal:  Br J Cancer Suppl       Date:  1988-12

Review 8.  Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology.

Authors:  Chenguang Wang; Michael P Lisanti; D Joshua Liao
Journal:  Cell Cycle       Date:  2011-01-01       Impact factor: 4.534

9.  Tumors induced in mice by direct inoculation of plasmid DNA expressing both activated H-ras and c-myc.

Authors:  Li Sheng-Fowler; Fang Cai; Haiqing Fu; Yong Zhu; Brian Orrison; Gideon Foseh; Don G Blair; Stephen H Hughes; John M Coffin; Andrew M Lewis; Keith Peden
Journal:  Int J Biol Sci       Date:  2010-03-29       Impact factor: 6.580

10.  deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo.

Authors:  Oleksi Petrenko; Alexander Zaika; Ute M Moll
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.